Display options
Cite
Agarwal S, Gupta M, Gunn S. USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION. AACE Clin Case Rep. 2019;5(3):e187-e191doi: 10.4158/ACCR-2018-0493.
Agarwal, S., Gupta, M., & Gunn, S. (2019). USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION. AACE clinical case reports, 5(3), e187-e191. https://doi.org/10.4158/ACCR-2018-0493
Agarwal, Swashti, et al. "USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION." AACE clinical case reports vol. 5,3 (2019): e187-e191. doi: https://doi.org/10.4158/ACCR-2018-0493
Agarwal S, Gupta M, Gunn S. USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION. AACE Clin Case Rep. 2019 Apr 25;5(3):e187-e191. doi: 10.4158/ACCR-2018-0493. eCollection 2019. PMID: 31967031; PMCID: PMC6876942.
Copy Download .nbib Format: NLM
Share it on

AACE Clin Case Rep. 2019 Apr 25;5(3):e187-e191. doi: 10.4158/ACCR-2018-0493. eCollection 2019.

USE OF INHALED INSULIN IN A PATIENT WITH SUBCUTANEOUS INSULIN RESISTANCE SYNDROME: A RARE CONDITION.

AACE clinical case reports

Swashti Agarwal, Meenal Gupta, Sheila Gunn

PMID: 31967031 PMCID: PMC6876942 DOI: 10.4158/ACCR-2018-0493

Abstract

OBJECTIVE: Subcutaneous insulin resistance syndrome (SIRS) is a rare entity, characterized by increased resistance to subcutaneous insulin and normal sensitivity to intravenous insulin, with no increase in circulating insulin antibodies. Little is known about its pathophysiology, but it has been suggested to occur due to rapid subcutaneous degradation of insulin. Multiple treatment modalities have been used in the past to treat this condition.

METHODS: We illustrate a case of a 17-year-old girl with type 1 diabetes mellitus (T1DM), presenting with recurrent episodes of diabetic ketoacidosis (DKA) due to resistance to subcutaneously delivered insulin.

RESULTS: We describe the challenges faced while attempting different modalities during her hospital stay, and eventually using inhaled insulin, which was recently approved by the Food and Drug Administration for use in nonpregnant adults with T1DM.

CONCLUSION: SIRS is a difficult condition that may lead to patient frustration and carries a serious risk of recurrent DKA. We described this case to create awareness about SIRS, provide insight into the challenges of its management, and report the use of inhaled insulin to successfully dose meal-time insulin, along with intramuscular glargine for basal insulin.

Copyright © 2019 AACE.

Conflict of interest statement

DISCLOSURE The authors have no multiplicity of interest to disclose.

References

  1. Diabetes Technol Ther. 2009 Nov;11(11):697-705 - PubMed
  2. Ann Surg. 1985 Sep;202(3):278-82 - PubMed
  3. Diabetes Care. 1981 May-Jun;4(3):366-76 - PubMed
  4. Diabetologia. 1982 Oct;23(4):333-6 - PubMed
  5. Diabetes Res Clin Pract. 2001 Dec;54(3):209-12 - PubMed
  6. Br Med J (Clin Res Ed). 1981 Nov 7;283(6301):1207-9 - PubMed
  7. J Diabetes Sci Technol. 2010 Mar 01;4(2):419-28 - PubMed
  8. N Engl J Med. 1981 Aug 13;305(7):363-8 - PubMed
  9. Pediatr Diabetes. 2010 Sep;11(6):380-2 - PubMed
  10. Diabetes Metab. 2005 Nov;31(5):496-8 - PubMed
  11. Diabet Med. 1997 Jan;14(1):63-72 - PubMed
  12. Diabetes. 1979 Jul;28(7):640-5 - PubMed
  13. Diabetes Metab. 2003 Nov;29(5):539-46 - PubMed
  14. Ann Intern Med. 2006 Nov 7;145(9):665-75 - PubMed
  15. J Pediatr Endocrinol Metab. 2008 Jun;21(6):555-68 - PubMed
  16. Diabetes Care. 2004 Nov;27(11):2622-7 - PubMed
  17. Diabetes Care. 2004 Oct;27(10):2356-62 - PubMed
  18. Diabetes Care. 2005 May;28(5):1077-82 - PubMed
  19. Diabetes Care. 1983 May-Jun;6(3):279-84 - PubMed

Publication Types